New Granted MannKind Patent 8/9/2016

[Deleted]

Monoclonal antibodies and diagnostic uses thereof

Type: Grant
Filed: August 5, 2014
Date of Patent: August 9, 2016
Assignee: MANNKIND CORPORATION
Inventors: Nathalie Kertesz, Sutao Zhu, Chih-Sheng Chiang

patents.justia.com/patent/9410957


Sleeping giant is slowing waking...

[Deleted]

Amgen loves MannKind.

•Nathalie Kertesz
— Currently works for Amgen Oct 2013 - Present
— Amgen’s Repatha Global Publication Plan Lead
— Former MannKind employee Jan 2005 - May 2011

[Deleted]

Speculation time—Amgen and MannKind have more than just former employees in common. They each have a bad history with Sanofi. Actually, each are still dealing with their Sanofi related events. Unfortunately, I am not going to look into how many past MannKind employees now work at Amgen or have worked at Amgen or vise versa, but we know at least one does. Amgen unfortunately had to close their campus in Seattle not too long ago which included Immunex too I believe. Castagna to the rescue. Andrea Leone-Bay to someone else's rescue?

[anderson]

Mango if you are going to mention former Amgen employees of note to speculate why not mention
Mike Castagna
Vice President, Global Commercial Lead, Biosimilar Business
Amgen
March 2014 – March 2016 (2 years 1 month)

[Deleted]

Aug 9, 2016 19:35:13 GMT -5 anderson said:

Mango if you are going to mention former Amgen employees of note to speculate why not mention
Mike Castagna
Vice President, Global Commercial Lead, Biosimilar Business
Amgen
March 2014 – March 2016 (2 years 1 month)

I kinda hinted to that when I said, "Castagna to the rescue?" aka MannKind's resue. And Andrea to Amgen's rescue. End result = RLS. 
Nathalie Kertesz is a current Amgen employee, and a former MannKind employee. Kinda all makes sense, and I think I mentioned this theory a long time ago here too.

[cm5]

More on this patent:
www.google.com/patents/US8846872

Monoclonal antibodies and diagnostic uses thereof

The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.

The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In particular, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.

BACKGROUND

The American Cancer Society has estimated that almost 1.5 million new cases of cancer will be diagnosed this year. This includes carcinoma in situ of the urinary bladder but excludes those of other sites such as basal and squamous cell skin cancers. Approximately one out of every two American men and one out of every three American women will have some type of cancer at some point during their lifetime.

One means of targeting cancer is by early screening and detection as well as diagnosis at an early disease stage which allow for treatment and prevention of later stage disease. A number of cancers when detected, screened or diagnosed early, can be more successfully treated. Although a number of therapeutic remedies exist, a continuing need remains for additional tools to better aid in preventing, screening, diagnosing and targeting a cancer with the appropriate therapeutic regimen. Such tools, for example, involve tumor-associated antigens of the cancer testis family against which both humoral and cellular immune responses have been observed in patients with different types of cancers.

Clinical trials on the use of tumor-associated antigen-specific vaccines are underway and show promising preliminary results. For a vaccine which is used to treat tumors expressing the targeted tumor-associated antigens, it can be useful to determine which TAA are expressed by a patient's tumor. Detecting the level of expression of specific TAAs in tumor tissues provide a convenient method to obtain the expression profile of TAAs in a patient's tumor. Hence diagnostic tools that can complement such cancer therapies are of value.

PRAME expression is noted in the nucleus. In addition to being expressed in acute myeloid leukemias, PRAME is also known to be expressed in solid, soft tissue, hematological and metastatic tumors. PRAME is also highly expressed in a number of conditions and/or diseases such as, but not limited to, breast, ovarian, prostate, melanoma, pancreatic, renal, and colorectal cancers. PRAME is also highly expressed in lymphomas including Hodgkin's lymphomas, peripheral T/NK cell lymphomas, anaplastic large cell lymphomas, and peripheral B cell lymphomas, but not in non-Hodgkin's lymphomas. High expression of PRAME has been noted in synovial sarcomas. PRAME is also highly expressed in colon carcinomas and liver metastasis from colorectal cancer and can be a viable target for metastatic colorectal cancer as well as for metastatic disease in other cancers.